Caroline Corner's questions to STEM (STEM) leadership • Q2 2015
Question
Caroline Corner of Cantor Fitzgerald asked if the new analysis of the five Phase I/II AMD patients who would qualify for the Radiant study was helping with site enrollment. She also questioned the day-to-day impact on the company's business plan following the dismissal of the patent infringement case against Neuralstem.
Answer
President and COO Dr. Ian Massey responded that while there was already enthusiasm from sites, the new data is recent and will be shared with investigators, which he believes will be reassuring for both them and for patients. CEO Martin McGlynn reiterated that the patent case decision has no impact on the company's ability to execute its business plan, as it was about another party's ability to operate, not their own.